Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice: A Novel Mechanism Presenting the Protein Fe65 as a Target

Titanilla Szögi, Ildikó Schuster, Emőke Borbély, Andrea Gyebrovszki, Z. Bozsó, János Gera, R. Rajkó, Miklós Sántha, B. Penke, L. Fülöp

Research output: Article

Abstract

Regulated intramembrane proteolysis (RIP) of the amyloid precursor protein (APP) leads to the formation of fragments, among which the intracellular domain of APP (AICD) was also identified to be a causative of early pathological events. AICD-counteracting proteins, such as Fe65, may serve as alternative therapeutic targets of Alzheimer's disease (AD). The detection of elevated levels of Fe65 in the brains of both human patients and APP transgenic mice may further strengthen the hypothesis that influencing the interaction between Fe65 and APP may have a beneficial effect on the course of AD. Based on a PXP motif, proven to bind to the WW domain of Fe65, a new pentapeptide was designed and tested. The impedimental effect of P33 on the production of beta amyloid (Aβ) (soluble fraction and aggregated plaques) and on the typical features of the AD pathology (decreased dendritic spine density, synaptic markers, elevated inflammatory reactions) was also demonstrated. Significant enhancements of both learning ability and memory function were observed in a Morris water maze paradigm. The results led us to formulate the theory that P33 acts by altering the conformation of Fe65 via binding to its WW domain, consequently hindering any interactions between Fe65 and key members involved in APP processing.

Original languageEnglish
JournalInternational journal of molecular sciences
Volume20
Issue number12
DOIs
Publication statusPublished - jún. 22 2019

Fingerprint

Neuronal Plasticity
Amyloid beta-Protein Precursor
plastic properties
Transgenic Mice
Plasticity
mice
proteins
Proteins
Data storage equipment
Alzheimer Disease
Proteolysis
Dendritic Spines
Aptitude
Pathology
spine
Amyloid
pathology
Conformations
Brain
markers

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice : A Novel Mechanism Presenting the Protein Fe65 as a Target. / Szögi, Titanilla; Schuster, Ildikó; Borbély, Emőke; Gyebrovszki, Andrea; Bozsó, Z.; Gera, János; Rajkó, R.; Sántha, Miklós; Penke, B.; Fülöp, L.

In: International journal of molecular sciences, Vol. 20, No. 12, 22.06.2019.

Research output: Article

@article{58acdb8eb68b4630a49f703e08a6cf32,
title = "Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice: A Novel Mechanism Presenting the Protein Fe65 as a Target",
abstract = "Regulated intramembrane proteolysis (RIP) of the amyloid precursor protein (APP) leads to the formation of fragments, among which the intracellular domain of APP (AICD) was also identified to be a causative of early pathological events. AICD-counteracting proteins, such as Fe65, may serve as alternative therapeutic targets of Alzheimer's disease (AD). The detection of elevated levels of Fe65 in the brains of both human patients and APP transgenic mice may further strengthen the hypothesis that influencing the interaction between Fe65 and APP may have a beneficial effect on the course of AD. Based on a PXP motif, proven to bind to the WW domain of Fe65, a new pentapeptide was designed and tested. The impedimental effect of P33 on the production of beta amyloid (Aβ) (soluble fraction and aggregated plaques) and on the typical features of the AD pathology (decreased dendritic spine density, synaptic markers, elevated inflammatory reactions) was also demonstrated. Significant enhancements of both learning ability and memory function were observed in a Morris water maze paradigm. The results led us to formulate the theory that P33 acts by altering the conformation of Fe65 via binding to its WW domain, consequently hindering any interactions between Fe65 and key members involved in APP processing.",
keywords = "Alzheimer’s disease, amyloid beta peptide, amyloid beta precursor protein, Fe65 protein, proline-rich peptide, WW domain",
author = "Titanilla Sz{\"o}gi and Ildik{\'o} Schuster and Emőke Borb{\'e}ly and Andrea Gyebrovszki and Z. Bozs{\'o} and J{\'a}nos Gera and R. Rajk{\'o} and Mikl{\'o}s S{\'a}ntha and B. Penke and L. F{\"u}l{\"o}p",
year = "2019",
month = "6",
day = "22",
doi = "10.3390/ijms20123050",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice

T2 - A Novel Mechanism Presenting the Protein Fe65 as a Target

AU - Szögi, Titanilla

AU - Schuster, Ildikó

AU - Borbély, Emőke

AU - Gyebrovszki, Andrea

AU - Bozsó, Z.

AU - Gera, János

AU - Rajkó, R.

AU - Sántha, Miklós

AU - Penke, B.

AU - Fülöp, L.

PY - 2019/6/22

Y1 - 2019/6/22

N2 - Regulated intramembrane proteolysis (RIP) of the amyloid precursor protein (APP) leads to the formation of fragments, among which the intracellular domain of APP (AICD) was also identified to be a causative of early pathological events. AICD-counteracting proteins, such as Fe65, may serve as alternative therapeutic targets of Alzheimer's disease (AD). The detection of elevated levels of Fe65 in the brains of both human patients and APP transgenic mice may further strengthen the hypothesis that influencing the interaction between Fe65 and APP may have a beneficial effect on the course of AD. Based on a PXP motif, proven to bind to the WW domain of Fe65, a new pentapeptide was designed and tested. The impedimental effect of P33 on the production of beta amyloid (Aβ) (soluble fraction and aggregated plaques) and on the typical features of the AD pathology (decreased dendritic spine density, synaptic markers, elevated inflammatory reactions) was also demonstrated. Significant enhancements of both learning ability and memory function were observed in a Morris water maze paradigm. The results led us to formulate the theory that P33 acts by altering the conformation of Fe65 via binding to its WW domain, consequently hindering any interactions between Fe65 and key members involved in APP processing.

AB - Regulated intramembrane proteolysis (RIP) of the amyloid precursor protein (APP) leads to the formation of fragments, among which the intracellular domain of APP (AICD) was also identified to be a causative of early pathological events. AICD-counteracting proteins, such as Fe65, may serve as alternative therapeutic targets of Alzheimer's disease (AD). The detection of elevated levels of Fe65 in the brains of both human patients and APP transgenic mice may further strengthen the hypothesis that influencing the interaction between Fe65 and APP may have a beneficial effect on the course of AD. Based on a PXP motif, proven to bind to the WW domain of Fe65, a new pentapeptide was designed and tested. The impedimental effect of P33 on the production of beta amyloid (Aβ) (soluble fraction and aggregated plaques) and on the typical features of the AD pathology (decreased dendritic spine density, synaptic markers, elevated inflammatory reactions) was also demonstrated. Significant enhancements of both learning ability and memory function were observed in a Morris water maze paradigm. The results led us to formulate the theory that P33 acts by altering the conformation of Fe65 via binding to its WW domain, consequently hindering any interactions between Fe65 and key members involved in APP processing.

KW - Alzheimer’s disease

KW - amyloid beta peptide

KW - amyloid beta precursor protein

KW - Fe65 protein

KW - proline-rich peptide

KW - WW domain

UR - http://www.scopus.com/inward/record.url?scp=85068771425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068771425&partnerID=8YFLogxK

U2 - 10.3390/ijms20123050

DO - 10.3390/ijms20123050

M3 - Article

C2 - 31234498

AN - SCOPUS:85068771425

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

ER -